Researchers create efficient iron photocatalyst for drug synthesis

Scientists at Nagoya University have developed an iron-based photocatalyst that reduces reliance on rare metals in organic synthesis. The new design uses fewer costly chiral ligands and enables the first asymmetric total synthesis of (+)-heitziamide A. This advance promotes more sustainable chemical reactions under blue LED light.

Researchers at Nagoya University's Graduate School of Engineering, led by Professor Kazuaki Ishihara, Assistant Professor Shuhei Ohmura, and graduate student Hayato Akao, have introduced a redesigned iron photocatalyst. Published in the Journal of the American Chemical Society in 2026, the study details how this catalyst cuts the use of chiral ligands by two thirds compared to their 2023 version, which required three per iron atom despite only one contributing to enantioselectivity.

The new system incorporates affordable achiral bidentate ligands with chiral ones to form an iron(III) salt structure. This setup enhances catalytic performance and directs the three-dimensional configuration of products. Activated by energy-efficient blue LED light, it facilitates a controlled radical cation (4 + 2) cyclization, forming six-membered rings with 1,2,3,5-substituted adducts common in natural products.

Using this catalyst, the team achieved the first total asymmetric synthesis of (+)-heitziamide A, a compound from medicinal plants that suppresses respiratory bursts. Prior syntheses had not produced the natural enantiomer asymmetrically. The mirror-image catalyst could similarly yield (-)-heitziamide A.

"The new catalyst design represents the definitive form of chiral iron(III) photoredox catalysts," Ohmura stated. "We believe this achievement marks a significant milestone in advancing iron-based photocatalysis."

Ishihara added, "Achieving the first-ever asymmetric total synthesis of (+)-heitziamide A using this catalytic reaction is a remarkable accomplishment." The approach allows construction of complex molecules, including pharmaceutical precursors, with abundant iron instead of scarce metals like ruthenium and iridium.

This development suggests potential for enantioselective synthesis of additional bioactive substances via the same cycloaddition step.

Labaran da ke da alaƙa

Researchers at the University of Santiago de Compostela report a light-driven method that directly “allylates” methane—adding an allyl group that can be used to build more complex molecules—and they demonstrate the approach by producing the nonsteroidal estrogen dimestrol from methane.

An Ruwaito ta hanyar AI An Binciki Gaskiya

Scientists at Oregon State University say they have engineered an iron-based nanomaterial that exploits acidic, peroxide-rich conditions inside tumors to generate two types of reactive oxygen species and kill cancer cells while largely sparing healthy cells. In mouse tests using human breast-cancer tumors, the team reports complete tumor regression without observable adverse effects, though the work remains preclinical.

Researchers at Florida State University have created a novel crystalline material that exhibits complex swirling magnetic behaviors not found in its parent compounds. By blending two structurally mismatched but chemically similar materials, the team induced atomic spins to form skyrmion-like textures. This breakthrough, detailed in the Journal of the American Chemical Society, could advance data storage and quantum technologies.

An Ruwaito ta hanyar AI

As detailed in the initial report on this breakthrough, experts at a Beijing evaluation conference on Tuesday praised the 'off-field electrocatalysis' technology developed by academician Li Can's team at the Dalian Institute of Chemical Physics. They recommended immediate industrial scale-up, following over 1,000 hours of uninterrupted operation at a Xinxiang pilot plant that eliminates nearly 100% of hydrogen sulfide emissions while producing high-value hydrogen and sulfur.

 

 

 

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi